Loss of H3K27me3 Expression Enriches in Recurrent Grade 1&2 Meningiomas and Maintains As a Biomarker Stratifying Progression Risk

Overview

Journal J Neurooncol

Publisher Springer

Date 2022 Nov 4

PMID 36329368

Authors

Lingyang Hua

Leihao Ren

Qian Wu

Jiaojiao Deng

Jiawei Chen

Haixia Cheng

Daijun Wang

Hong Chen

Qing Xie

Hiroaki Wakimoto

Ye Gong

Affiliations

Soon will be listed here.

Abstract

Purpose: To determine if loss of H3K27me3 could predict higher risk of re-recurrence in recurrent meningiomas.

Methods: A retrospective, single-center cohort study was performed for patients who underwent resection of recurrent grade 1 (N = 132) &2 (N = 32) meningiomas from 2009 to 2013. Association of H3K27me3 staining and clinical parameters was analyzed. Additionally, H3K27me3 staining was performed from 45 patients whose tumors recurred and were resected during the follow-up, to evaluate H3K27me3 change during tumor progression. Survival analysis was performed as well.

Results: Loss of H3K27me3 expression was observed in 83 patients, comprising 63 grade 1 (47.7%) and 20 grade 2 patients (62.5%). Both grade 1 (p < 0.001) and grade 2 recurrent meningiomas (p < 0.001) had a higher frequency of H3K27me3 loss, compared to de novo meningiomas. 8 of 27 tumors with retained H3K27me3 lost H3K27me3 during re-recurrence (29.6%), while no gain of H3K27me3 was observed in progressive disease from 18 tumors with H3K27me3 loss. Loss of H3K27me3 expression was associated with an earlier re-recurrence in recurrent meningiomas grade 1 and 2 (p < 0.001), and was an independent prognostic factor for PFS in recurrent grade 1 meningiomas (p = 0.005).

Conclusion: Compared to primary meningiomas, recurrent meningiomas more predominantly had loss of H3K27me3 expression, and further loss can occur during the progression of recurrent tumors. Our results further demonstrated that loss of H3K27me3 predicted shorter PFS in recurrent grade 1 and grade 2 meningiomas. Our work thus supports clinical testing of H3K27me3 in recurrent meningiomas WHO grade 1 and 2.

Citing Articles

cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas.

Sahm F, Aldape K, Brastianos P, Brat D, Dahiya S, von Deimling A Neuro Oncol. 2024; 27(2):319-330.

PMID: 39212325 PMC: 11812049. DOI: 10.1093/neuonc/noae170.

The Impact of Molecular and Genetic Analysis on the Treatment of Patients with Atypical Meningiomas.

Ravnik J, Rowbottom H Diagnostics (Basel). 2024; 14(16).

PMID: 39202270 PMC: 11353905. DOI: 10.3390/diagnostics14161782.

Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis.

Aung T, Ngamjarus C, Proungvitaya T, Saengboonmee C, Proungvitaya S PLoS One. 2024; 19(5):e0303337.

PMID: 38758750 PMC: 11101050. DOI: 10.1371/journal.pone.0303337.

Atypical meningioma: Histopathological, genetic, and epigenetic features to predict recurrence risk.

Marastoni E, Barresi V Histol Histopathol. 2023; 39(3):293-302.

PMID: 37921468 DOI: 10.14670/HH-18-670.

Loss of H3K27me3 in meningiomas: an independent marker for CNS WHO grade 2?.

Behling F, Passlack P, Fodi C, Hielscher T, Schittenhelm J, Nassiri F Neurooncol Adv. 2023; 5(1):vdad112.

PMID: 37727848 PMC: 10506376. DOI: 10.1093/noajnl/vdad112.

References

Ostrom Q, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan J . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro Oncol. 2021; 23(12 Suppl 2):iii1-iii105. PMC: 8491279. DOI: 10.1093/neuonc/noab200. View

Brastianos P, Galanis E, Butowski N, Chan J, Dunn I, Goldbrunner R . Advances in multidisciplinary therapy for meningiomas. Neuro Oncol. 2019; 21(Suppl 1):i18-i31. PMC: 6347080. DOI: 10.1093/neuonc/noy136. View

Hua L, Zhu H, Li J, Tang H, Kuang D, Wang Y . Prognostic value of estrogen receptor in WHO Grade III meningioma: a long-term follow-up study from a single institution. J Neurosurg. 2017; 128(6):1698-1706. DOI: 10.3171/2017.2.JNS162566. View

Shakir S, Souhami L, Petrecca K, Mansure J, Singh K, Panet-Raymond V . Prognostic factors for progression in atypical meningioma. J Neurosurg. 2018; 129(5):1240-1248. DOI: 10.3171/2017.6.JNS17120. View

Simonetti G, Silvani A, Tramacere I, Farinotti M, Legnani F, Pinzi V . Long term follow up in 183 high grade meningioma: A single institutional experience. Clin Neurol Neurosurg. 2021; 207:106808. DOI: 10.1016/j.clineuro.2021.106808. View

Spille D, Hess K, Bormann E, Sauerland C, Brokinkel C, Warneke N . Risk of tumor recurrence in intracranial meningiomas: comparative analyses of the predictive value of the postoperative tumor volume and the Simpson classification. J Neurosurg. 2020; 134(6):1764-1771. DOI: 10.3171/2020.4.JNS20412. View

Unterberger A, Nguyen T, Duong C, Kondajji A, Kulinich D, Yang I . Meta-analysis of adjuvant radiotherapy for intracranial atypical and malignant meningiomas. J Neurooncol. 2021; 152(2):205-216. DOI: 10.1007/s11060-020-03674-7. View

Wang D, Sun S, Hua L, Deng J, Luan S, Cheng H . Prognostic Model That Predicts Benefits of Adjuvant Radiotherapy in Patients With High Grade Meningioma. Front Oncol. 2020; 10:568079. PMC: 7683714. DOI: 10.3389/fonc.2020.568079. View

Zhu H, Bi W, Aizer A, Hua L, Tian M, Den J . Efficacy of adjuvant radiotherapy for atypical and anaplastic meningioma. Cancer Med. 2019; 8(1):13-20. PMC: 6346222. DOI: 10.1002/cam4.1531. View

10.

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

11.

Nassiri F, Liu J, Patil V, Mamatjan Y, Wang J, Hugh-White R . A clinically applicable integrative molecular classification of meningiomas. Nature. 2021; 597(7874):119-125. PMC: 11604310. DOI: 10.1038/s41586-021-03850-3. View

12.

Sahm F, Schrimpf D, Stichel D, Jones D, Hielscher T, Schefzyk S . DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 2017; 18(5):682-694. DOI: 10.1016/S1470-2045(17)30155-9. View

13.

Suppiah S, Nassiri F, Bi W, Dunn I, Hanemann C, Horbinski C . Molecular and translational advances in meningiomas. Neuro Oncol. 2019; 21(Suppl 1):i4-i17. PMC: 6347079. DOI: 10.1093/neuonc/noy178. View

14.

Bi W, Abedalthagafi M, Horowitz P, Agarwalla P, Mei Y, Aizer A . Genomic landscape of intracranial meningiomas. J Neurosurg. 2016; 125(3):525-35. DOI: 10.3171/2015.6.JNS15591. View

15.

Daoud E, Zhu K, Mickey B, Mohamed H, Wen M, DeLorenzo M . Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management. Acta Neuropathol Commun. 2022; 10(1):56. PMC: 9020042. DOI: 10.1186/s40478-022-01362-3. View

16.

Kim J, Hwang K, Kwon H, Lee J, Lee K, Choe G . Clinicopathologic Characteristics of Grade 2/3 Meningiomas: A Perspective on the Role of Next-Generation Sequencing. Front Oncol. 2022; 12:885155. PMC: 9236884. DOI: 10.3389/fonc.2022.885155. View

17.

Katz L, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R . Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol. 2018; 135(6):955-963. DOI: 10.1007/s00401-018-1844-9. View

18.

Hua L, Wang D, Zhu H, Deng J, Luan S, Chen H . Long-term outcomes of multimodality management for parasagittal meningiomas. J Neurooncol. 2020; 147(2):441-450. DOI: 10.1007/s11060-020-03440-9. View

19.

Behling F, Fodi C, Gepfner-Tuma I, Kaltenbach K, Renovanz M, Paulsen F . H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort. Neuro Oncol. 2020; 23(8):1273-1281. PMC: 8328015. DOI: 10.1093/neuonc/noaa303. View

20.

Gauchotte G, Peyre M, Pouget C, Cazals-Hatem D, Polivka M, Rech F . Prognostic Value of Histopathological Features and Loss of H3K27me3 Immunolabeling in Anaplastic Meningioma: A Multicenter Retrospective Study. J Neuropathol Exp Neurol. 2020; 79(7):754-762. DOI: 10.1093/jnen/nlaa038. View